Feasibility and Safety of CT-guided Intrathoracic and Bone Re-biopsy for Non-small Cell Lung Cancer

Aim: This study aimed to retrospectively determine the feasibility and safety of computed tomography (CT)-guided intrathoracic and bone re-biopsy for patients with non-small cell lung cancer (NSCLC). Materials and Methods: Seventeen patients underwent CT-guided intrathoracic or bone re-biopsy for the determination of epidermal growth factor receptor (EGFR) T790M mutation and/or programmed cell death-ligand 1 (PD-L1) expression. The characteristics of each lesion, success rate of analyses, and complications were investigated. Results: Specimens from 16 out of the 17 patients were adequate for evaluation of EGFR T790M mutation and/or PD-L1 expression. The mean diameter of the lesions was 40 mm, the mean procedural time was 24 minutes, and the median number of punctures was 2. There were no significant differences in lesion characteristics and success rates between CT-guided intrathoracic and bone re-biopsies. No serious complications occurred. Conclusion: Both CT-guided intrathoracic and bone re-biopsies for patients with NSCLC were feasible and safe.

[1]  J. Goo,et al.  Repeat biopsy of patients with acquired resistance to EGFR TKIs: implications of biopsy-related factors on T790M mutation detection , 2018, European Radiology.

[2]  F. Abtin,et al.  Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung Cancer. , 2017, Radiology.

[3]  Y. Maehara,et al.  Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab. , 2017, Anticancer research.

[4]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[5]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[6]  H. Saka,et al.  Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study. , 2016, Lung cancer.

[7]  T. Nakajima,et al.  Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure , 2016, Cancer science.

[8]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[9]  Y. Hiraishi,et al.  Bronchoscopic Re-biopsy for Mutational Analysis of Non-small Cell Lung Cancer , 2016, Lung.

[10]  N. Chen,et al.  Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer , 2016, Scientific Reports.

[11]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[12]  Y. Yatabe,et al.  Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer , 2015, Scientific Reports.

[13]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[14]  G. Ferretti,et al.  Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC , 2015, Targeted Oncology.

[15]  J. Neal,et al.  Rociletinib in EGFR-mutated non-small-cell lung cancer. , 2015, The New England journal of medicine.

[16]  P. Jänne,et al.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.

[17]  C. Chouaid,et al.  Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01). , 2014, Lung cancer.

[18]  N. Girard,et al.  Mutational profiling of bone metastases from lung adenocarcinoma: results of a prospective study (POUMOS-TEC). , 2014, BoneKEy reports.

[19]  E. Smit,et al.  Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. , 2014, Lung cancer.

[20]  Ho Yun Lee,et al.  Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications. , 2012, Radiology.

[21]  J. Vernejoux,et al.  Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer: A French Prospective, Observational, Multicenter Study (GFPC 0601) , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  M. Ladanyi,et al.  Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay , 2011, Clinical Cancer Research.

[23]  R. Coleman.  Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.

[24]  K. Murata,et al.  CT-guided needle biopsy of lung lesions: a survey of severe complication based on 9783 biopsies in Japan. , 2006, European journal of radiology.

[25]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[26]  A. Manhire,et al.  Percutaneous lung biopsies: a survey of UK practice based on 5444 biopsies. , 2002, The British journal of radiology.

[27]  B. Daly,et al.  Real-time CT fluoroscopy: evolution of an interventional tool. , 1999, Radiology.

[28]  K. Katada,et al.  Guidance with real-time CT fluoroscopy: early clinical experience. , 1996, Radiology.

[29]  W. Sinner.  Complications of Percutaneous Transthoracic Needle Aspiration Biopsy , 1976, Acta radiologica: diagnosis.

[30]  D. Vanel,et al.  Percutaneous CT-guided biopsy of the musculoskeletal system: results of 2027 cases. , 2011, European journal of radiology.

[31]  G. Exner,et al.  Metastatic bone disease from occult carcinoma: a profile , 2004, International Orthopaedics.